<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669732</url>
  </required_header>
  <id_info>
    <org_study_id>DS8500-A-J205</org_study_id>
    <nct_id>NCT02669732</nct_id>
  </id_info>
  <brief_title>An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp</brief_title>
  <official_title>A Phase 2, Randomized, Placebo-controlled, Double-blind, Crossover Study of DS-8500a to Evaluate the Effects on Pancreatic Beta Cell Function in Japanese Patients With Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate change in insulin secretory capacity in patients
      with type 2 diabetes mellitus as determined by hyperglycemic clamp after a 28-day oral
      administration of DS-8500a at 75 mg in a placebo-controlled, 2 × 2 crossover study. In
      addition, safety of this regimen will be examined in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First-phase and Second-phase secretion Insulin</measure>
    <time_frame>Baseline to Day 28 (Period 1 and 2)</time_frame>
    <description>First-phase and Second-phase secretion Insulin Baseline to Day 28 (Period 1 and 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First-phase and Second-phase secretion C-peptide</measure>
    <time_frame>Baseline to Day 28 (Period 1 and 2)</time_frame>
    <description>First-phase and Second-phase secretion (C-peptide)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>M value</measure>
    <time_frame>Baseline to Day 28 (Period 1 and 2)</time_frame>
    <description>M value：Mean of Glucose Infusion Rate from 90 to 120 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M/I value</measure>
    <time_frame>Baseline to Day 28 (Period 1 and 2)</time_frame>
    <description>M/I value：M value / steady-state Insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disposition Index</measure>
    <time_frame>Baseline to Day 28 (Period 1 and 2)</time_frame>
    <description>Disposition Index：Product of M value and First-phase secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of Adverse Events</measure>
    <time_frame>Day 28 (Period 1 and 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma concentration of DS-8500a</measure>
    <time_frame>Day 28 (Period 1 and 2)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DS-8500a 75 mg once daily (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablets, orally, once daily for up to 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablets, orally, once daily for up to 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8500a</intervention_name>
    <description>tablets</description>
    <arm_group_label>DS-8500a 75 mg once daily (QD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 20 years at the time of informed consent

          -  Japanese patients with type 2 diabetes

          -  Patients who have HbA1c ≥ 7.0% and &lt; 9.0%

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or
             ketoacidosis

          -  Patients receiving or requiring treatment with insulin

          -  Patients with a body mass index (BMI) of &lt; 18.5 kg/m2 or ≥ 35.0 kg/m2

          -  Patients with clinically evident renal impairment (estimated glomerular filtration
             rate [eGFR] of &lt; 45 mL/min per 1.73 m2) or clinically significant renal disease

          -  Patients with fasting plasma glucose ≥ 240 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hirotaka Watada, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juntendo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SOUSEIKAI Hakata Clinic</name>
      <address>
        <city>Hakata-ku</city>
        <state>Fukuoka</state>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Adult</keyword>
  <keyword>Developmental Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>DS-8500a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

